Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Matthew Tall | Researchclopedia

Back to researchers

Matthew Tall

Institute of Cancer Research

15

Works

186

Citations

5

h-index

3

i10-index

Research Topics

Histone Deacetylase Inhibitors Research Protein Degradation and Inhibitors Epigenetics and DNA Methylation

Affiliations

Royal Marsden NHS Foundation Trust2012–2012

Institute of Cancer Research2010–2024

Cancer Research UK2012–2015

Top Works

A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

Udai Banerji,Leni van Doorn,et al.

201278 citations

PI3K/AKT/mTOR signaling in cancer

Peptidase Inhibition and Analysis

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

Mike I. Walton,Paul D. Eve,et al.

201568 citations

Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.

Andrea Biondo,Tami Yap,et al.

201119 citations

Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors.

Paul Elvin,Amy L. Palmer,et al.

20147 citations

Abstract CT111: Pharmacokinetic and pharmacodynamic evaluation of NXP800, a novel GCN2 activator, in a first in human clinical trial

Simon Pacey,Ching Leung,et al.

20245 citations

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors.

Udai Banerji,Leni van Doorn,et al.

20104 citations

Abstract 27: First dose-finding study in cancer patients (pts) of a potent, selective, allosteric AKT inhibitor MK2206 (MK), incorporating pharmacodynamic (PD) and predictive biomarkers and showing profound pathway blockade

Timothy A. Yap,Kyriakos P. Papadopoulos,et al.

20103 citations

Abstract B044: Results of a phase 1 dose escalation clinical trial of NXP800, a novel GCN2 activator, in patients with advanced or metastatic solid tumors

Udai Banerji,Simon Pacey,et al.

20232 citations

Supplementary Materials from A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

Udai Banerji,Leni van Doorn,et al.

20230 citations